The transition from Ambrisentan to Macitentan to a selected cohort showed that the change is safe and improved exercise capacity, NT-pro BNP, and proper ventricular function with few SE like menstrual disorder and anemia which may necessitate monitoring and interventions in younger patients [13]. The gene discussed is NPPB; the disease is anemia (phenotype).